Dr. John Maraganore, CEO of Alnylam highlights the importance of diversity within his company and the biotech sector. Dr. John Maraganore has led a career pursuing therapies to address unmet medical needs. At Alnylam Pharmaceuticals, Maraganore is helping lead the development of RNAi therapeutics which aim to address genetic medicines, cardio-metabolic diseases and hepatic infectious diseases.